Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Good progress on all fronts

Micro-X
3:27pm
January 30, 2024
MX1 posted its 2Q24 report which showed a net operating cash inflow of A$4.3m which was boosted by the receipt of a R&D rebate of A$6.2m. Pleasingly, Mobile DR receipts are ticking up and project work with the ASA and DHA remain on track. Our focus remains on turning customer and distributor demonstrations of the Argus into sales. At this stage we have made no changes to our forecasts, valuation or target price of A$0.27. We maintain a Speculative Buy recommendation.

Wounded, but can be repaired

Aroa Biosurgery
3:27pm
January 30, 2024
ARX provided a disappointing update at its 3Q24 results, downgrading its FY24 revenue forecasts by ~8% and now expecting a small EBITDA loss (NZ$1-3m) for the year (was positive NZ$1-2m). The downgrade was due to an overestimation of revenue from its distribution partner, TELA Bio and a focus on selective procedures for Myriad. We have reduced our forecasts in line with guidance and have downgraded our target price to $1.20 (was $1.50) but retain our Add recommendation.

Flows trend improving

Netwealth Group
3:27pm
January 30, 2024
NWL reported 2Q24 FUA of A$78bn (+8.3% qoq; +24.6% pcp), with a ~A$3.4bn positive market move and net inflows of A$2.6bn (in-line with expectations). 2Q24 net inflows of A$2.6bn were up ~27% qoq and 25% on the pcp. Net inflows returned to more ‘normalised’ levels as gross outflows slowed. Pooled cash levels are stable (lower revenue margin) and NWL stepped up hiring (low job vacancies). We still expect some incremental margin improvement in 1H. NWL continues to execute and the opportunity runway remains long. The groups market position; earnings defensiveness; and growth outlook is strong, however, the stock is trading in-line with our valuation.

Not better yet, but moving before the evidence

Bapcor
3:27pm
January 29, 2024
BAP’s 1H24 NPAT is expected to be down 13-15% on pcp. Whilst below our forecast (~7%), the trading update was overall in-line with expectations. Retail was weak (EBITDA -13% on pcp), however in-line. Trade divisions +4-5%. BAP reconfirmed Better-than-Before (BTB) targets for 2H24, expecting A$7-10m NPAT. The exit run rate should be greater, given timing through the half. We see the trading update as providing some increased clarity of the core earnings trajectory/base. Whilst there is still earnings risk evident (Retail), FY25 is positioned to see earnings increase (vs FY23/24 which faced downside risks). Several factors remain against the BAP investment case: negative earnings momentum; recent CFO departure; and transformation targets which look unachievable. Whilst hard to hurdle, there is now arguably lower downside earnings risk and higher prospects for earnings improvement into FY25. Coupled with a reasonable valuation (16.5x a re-based FY24), we see this as providing enough risk/reward to accumulate ahead of the firm evidence of the earnings uplift. Upgrade to ADD recommendation.

A good base set for future growth

Frontier Digital Ventures
3:27pm
January 29, 2024
FDV has released its 4Q23 quarterly update. While 4Q23 group revenue was down -13% on the pcp, we saw the quarterly update as mirroring recent trends of a broadly robust performance from FDV’s consolidated businesses, held back by some continued headwinds in Zameen. We adjust our FDV FY23F/FY24F EPS by +2%/-1% on a broad review of our earnings assumptions. Our target price is unchanged at A$0.77. We continue to be attracted to FDV’s long-term growth profile and the earnings potential of the assembled portfolio. ADD rating maintained.

Bauna still delivers

Karoon Energy
3:27pm
January 29, 2024
A quarter with some challenges, in particular impacted Brazil volumes following a hydrate issue and subsequent mechanical failure at one of Bauna’s wells. KAR delivered a largely in-line December quarter operational and sales result. Despite issues Bauna achieved above midpoint of guidance production. Who Dat only contributed 11 days of production at the end of the period. We expect more data (and a much larger contribution) in future periods. We maintain an Add recommendation, with an unchanged A$2.80 Target Price.

A few challenges but the core remains strong

Woolworths
3:27pm
January 29, 2024
WOW’s trading update overall was weaker than anticipated. Management has guided to 1H24 group underlying EBIT of between $1,682m-1,699m, which at the mid-point was 2% below our forecast and 1% weaker than Visible Alpha (VA) consensus. While the company said Australian Food and PFD’s performance remained solid, it was a more challenging half for NZ Food and BIG W. We make minimal adjustments to FY24-26F group underlying earnings forecasts (reduction of between 0-1%), with upgrades to Australian Food and Australian B2B slightly more than offset by downgrades to NZ Food and BIG W. Our target price falls to $39.45 (from $39.90) and we maintain our Add rating. Despite the weakness in NZ Food and BIG W, our positive view on WOW remains predicated on a continued solid outlook for the core Australian Food segment.

Simplifying the medication journey

MedAdvisor
3:27pm
January 29, 2024
MedAdviser (MDR) is a medication management, pharmaceutical adherence and patient-pharmacist communication application that aims to simplify the way patients manage their medication. Following a number of transformative acquisitions over the last few years, Factset consensus expects solid revenue growth of 15%/13%/7% over FY24/25/26 respectively and importantly achieving profitability in FY25. MDR posted 1Q24 revenue of A$25.4m, up 27.0% and gross profit of A$15.7m up 30.8% with available funding of A$11.6m to achieve consensus growth of ~11.0% over the next three years.

Books Barossa budget boost

Santos
3:27pm
January 28, 2024
Struggling to contain costs within contingencies following multiple delays, STO increased its development capex budget for Barossa by US$200-$300m to US$4.5-$4.6bn. STO delivered an otherwise in-line 4Q23 result across production and revenue. Capex trailed following delays to Barossa. Net debt stood at US$4.3bn at the end of December. We maintain our Hold rating, viewing STO as having already been rewarded for perceived corporate appeal given current merger talks with peer WDS.

2Q beat; op leverage returns; GLP-1s benefit PAP

ResMed Inc
3:27pm
January 28, 2024
2Q results were above expectations, with double-digit top line and bottom line growth, improving operating leverage and strong cash flow. Devices grew above market (+11%), on strong demand and ex-US could-connected availability, while masks (+9%) tracked expectations, driven by resupply and new patient setups despite softer ex-US (+4% cc on a tough comp +14%). Operating margin expanded 190bp on pcp (first time in 11 quarters) and sequentially (+250bp) on improving gross profit margin and good cost control, with further gains expected. Management presented real-world data from 529k OSA patients prescribed GLP-1s showing an increased likelihood of not only starting PAP therapy, but also improving re-supply rates over time vs OSA patients not prescribed GLP-1s. We adjust FY24-26 forecasts modestly, with our target price rising to $32.82. Add.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more